二甲双胍治疗儿童及年轻成人范可尼贫血患者血细胞减少
该单中心研究纳入15例至少1系血细胞减少的非糖尿病范可尼贫血(FA)患者,14例符合条件接受二甲双胍治疗6个月,评估可行性与耐受性及血象改善。13/14(93%)耐受年龄最大剂量,无低血糖或代谢性酸中毒,无≥3级不良事件;可评估13例中4例(30.8%,90%CI 11.3-57.3)达血液学反应,中位起效时间84.5天。二甲双胍安全可耐受,可能提供治疗获益。
要点
- 14例非糖尿病FA患者接受二甲双胍6个月,13例(93%)耐受年龄最大剂量。
- 无低血糖、代谢性酸中毒或≥3级不良事件,无因毒性中断给药。
- 可评估13例中4例(30.8%,90%CI 11.3-57.3)达血液学反应,中位起效84.5天。
核心结论
- 二甲双胍在非糖尿病FA患者中安全且可耐受,可能提供治疗获益。
研究设计与样本
- 单中心研究,纳入15例至少1系血细胞减少(血红蛋白<10 g/dL;血小板计数<100 000 cells/µL;或绝对中性粒细胞计数<1000 cells/µL)的非糖尿病FA患者,其中14例符合条件接受二甲双胍治疗6个月。
- 中位年龄9.4岁(范围6.0-26.5)。
- 试验注册号NCT03398824。
主要发现
- 14例中13例(93%)耐受年龄最大剂量;1例因2级胃肠道症状减量。
- 无受试者出现低血糖或代谢性酸中毒;无因毒性中断给药;未观察到归因于二甲双胍的3级或以上不良事件。
- 基于改良骨髓增生异常综合征国际工作组标准,可评估13例中4例(30.8%;90%置信区间11.3-57.3)达血液学反应。
- 中位起效时间84.5天(范围71-128天);反应见于中性粒细胞(n=3)、血小板(n=1)和红细胞(n=1)。
- 治疗期间无受试者符合疾病进展或复发标准。
关键数值与推荐
- 入组血细胞减少标准:血红蛋白<10 g/dL;血小板计数<100 000 cells/µL;或绝对中性粒细胞计数<1000 cells/µL。
- 血液学反应评估采用改良骨髓增生异常综合征国际工作组标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fanconi anemia (FA), a genetic DNA repair disorder characterized by marrow failure and cancer susceptibility. In FA mice, metformin improves blood counts and delays tumor development. We conducted a single institution study of metformin in nondiabetic patients with FA to determine feasibility and tolerability of metformin treatment and to assess for improvement in blood counts. Fourteen of 15 patients with at least 1 cytopenia (hemoglobin < 10 g/dL; platelet count < 100 000 cells/µL; or an absolute neutrophil count < 1000 cells/µL) were eligible to receive metformin for 6 months. Median patient age was 9.4 years (range 6.0-26.5 ). Thirteen of 14 subjects (93%) tolerated maximal dosing for age; 1 subject had dose reduction for grade 2 gastrointestinal symptoms. No subjects developed hypoglycemia or metabolic acidosis. No subjects had dose interruptions caused by toxicity, and no grade 3 or higher adverse events attributed to metformin were observed. Hematologic response based on modified Myelodysplastic Syndrome International Working Group criteria was observed in 4 of 13 evaluable patients (30.8%; 90% confidence interval, 11.3-57.3). Median time to response was 84.5 days (range 71-128 days). Responses were noted in neutrophils (n = 3), platelets (n = 1), and red blood cells (n = 1). No subjects met criteria for disease progression or relapse during treatment. Correlative studies explored potential mechanisms of metformin activity in FA. Plasma proteomics showed reduction in inflammatory pathways with metformin. Metformin is safe and tolerable in nondiabetic patients with FA and may provide therapeutic benefit. This trial was registered at as #NCT03398824.
引用
- Pollard JA, Furutani E, Liu S, et al. Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Adv. 2022. PMID: 35500223. doi:10.1182/bloodadvances.2021006490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。